Pricing Log in Create free account
Friday 6 November 2026 Export PBH’s income statement to Excel — free account

Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.

Revenue
+22.7%
EPS
−38.4%
Free cash flow
−38.2%
Total debt
+100.9%

Quarter to September 2026, against a year earlier

44.63 8.65 −16.23%
Market cap
$2.1B
P/E
13.7×
Fwd P/E
11.7×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.19
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 — — 4 — — — — — —
Insider Ownership 1.72%

Capital & Financial Ratios $m

Size
Market Cap 2,100.00
Revenue ttm 1,167.08
Net income ttm 155.10
Free cash flow ttm 214.22
Net debt Q (46.51)
Valuation
P/E 13.69
Forward P/E 11.70
Price / sales 1.82
Forward P/S Powerpack
Price / FCF 9.90
Price / book 1.09
Financial health
Current ratio Q 2.92 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 3.77
Growth
Revenue growth Q +22.69% (above 0%: growing)
Operating income growth Q +1.31% (above 0%: growing)
EPS, this year +3.75%
EPS, next year A +12.21%
Revenue, next year A +17.02% (at or above 10%: strong)
EPS, past 5 yrs +3.77%
EPS, next 5 yrs A +6.53%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.5×, against a ten-year median of 3.9×; over the ten years it ranged from 3.0× in 2026 to 5.9× in 2017.
P/E against its own 10 years 27.87%
10-year low 10-year high
P/S against its own 10 years 10.56%
10-year low 10-year high
P/B against its own 10 years 0.04%
10-year low 10-year high
EV/Sales against its own 10 years 12.43%
10-year low 10-year high
EV/FCF against its own 10 years 52.33%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—
Growth, 2018–25
−100.0%/yr
  1. 0.48 ’18
  2. 0.00 ’20 −100
  3. 0.00 ’21
  4. 0.00 ’22
  5. 0.00 ’23
  6. 0.00 ’24
  7. 0.00 ’25
paid change on the year, % Powerpack

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 46 98 64 47
Receivables 177 194 192 244
Inventory 139 148 159 179
Other — — — —
375 448 431 492
2024 2025 2026 Q'26
Payables 39 19 23 44
ST’ Debt — — — —
Other — — — —
117 107 121 169

Compound Annual Growth %

10y 5y 3y
Sales 3.05% 2.91% (1.17%)
Cash Flow 3.87% 1.80% 3.90%
Earnings 6.66% 2.93% 0.00%
Book Value 9.75% 6.80% 9.26%

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate 0.89 Actual 0.98

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 0.97 1.07 Beat by 0.10
Q3 FY26 1.16 1.14 Miss by 0.02
Q4 FY26 1.39 1.23 Miss by 0.16
Q1 FY27 0.89 0.98 Beat by 0.09
Q2 FY27 1.06 — Reports 5 November 2026

EPS $

Jun Sep Dec Mar Year
’26 0.61 0.53 — — —
’26 0.95 0.86 0.97 1.13 3.91
’25 0.98 1.09 1.22 1.00 4.29
’24 1.06 1.07 1.06 0.98 4.17
’23 1.09 1.02 1.04 (4.83) (1.65)
’22 1.14 0.89 0.99 1.02 4.04
’21 0.86 0.88 0.81 0.70 3.25
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 266 336 — — —
’26 250 274 283 282 1,089
’25 267 284 290 297 1,138
’24 279 286 283 277 1,125
’23 277 289 276 286 1,128
’22 269 276 274 267 1,087
’21 229 237 239 238 943
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 71 38 — — —
’26 79 57 78 43 258
’25 55 70 65 62 252
’24 48 62 71 67 249
’23 58 58 55 59 230
’22 69 61 66 63 260
’21 75 52 49 59 236
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 67 34 — — —
’26 78 55 75 38 246
’25 54 68 64 58 243
’24 47 60 69 64 239
’23 57 55 53 56 222
’22 68 58 64 60 250
’21 73 43 43 54 213
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Sep ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 882 1,041 976 963 943 1,087 1,128 1,125 1,138 1,089 1,167 +2.4% 1,274 1,351 1,326 +6.8%
Gross margin, % 56.72 55.37 56.94 57.34 58.03 57.11 55.45 55.49 55.76 54.71 52.47 (2.0) pt
EBT 111 107 (38) 191 204 262 (94) 276 284 257 213 +9.8%
EBT margin, % 12.57 10.29 (3.90) 19.85 21.64 24.15 (8.33) 24.53 24.98 23.65 18.21 +11.1 pt
Net income 69 340 (36) 142 165 205 (82) 209 215 190 155 +11.9%
Per share, $
Per share, $ Revenue 16.65 19.61 18.74 18.99 18.79 21.62 22.60 22.62 22.89 22.47 24.57 +3.4%
Earnings 1.31 6.40 (0.69) 2.81 3.28 4.09 (1.65) 4.21 4.32 3.93 3.26 +13.0%
Cash flow 2.81 3.96 3.64 4.28 4.69 5.17 4.60 5.00 5.06 5.32 4.84 +7.4%
Capex (0.05) (0.24) (0.20) (0.29) (0.44) (0.19) (0.16) (0.19) (0.17) (0.23) (0.33) +17.4%
Free cash flow 2.75 3.72 3.43 3.99 4.25 4.98 4.45 4.81 4.90 5.09 4.51 +7.1%
Book value 15.53 22.20 21.05 23.09 27.05 31.39 29.01 33.26 36.92 38.95 40.94 +10.8%
Shares, m 53 53 52 51 50 50 50 50 50 48 48 (1.0%)
Valuation, ×
Valuation, × P/E 42.09 5.16 0.00 13.01 13.44 12.98 0.00 17.03 19.90 15.04 13.69 13.9
P/S 3.34 1.68 1.57 1.93 2.35 2.45 2.77 3.17 3.76 2.64 1.82 2.6
P/B 3.58 1.49 1.39 1.59 1.63 1.69 2.16 2.15 2.33 1.52 1.09 2.0
EV/Sales 5.79 3.57 3.39 3.64 3.90 3.79 3.92 4.14 4.57 3.52 3.52 4.0
EV/FCF 35.01 18.83 18.50 17.32 17.23 16.48 19.93 19.45 21.36 15.54 19.18 20.0
Cash, $m
Cash, $m Operating cash flow 149 210 189 217 236 260 230 249 252 258 230 +6.3%
Capex (3) (13) (10) (15) (22) (10) (8) (10) (8) (11) (16) +16.2%
Free cash flow 146 198 179 203 213 250 222 239 243 246 214 +6.0%
Balance, $m
Balance, $m Working capital 172 180 174 216 148 150 231 258 342 311 324 +6.8%
Net debt 2,152 1,960 1,771 1,640 1,454 1,454 1,289 1,080 915 948 (47) (8.7%)
Shareholders’ equity 823 1,179 1,096 1,171 1,358 1,578 1,447 1,655 1,835 1,888 1,945 +9.7%
Returns, %
Returns, % ROA 2.02 8.85 (0.99) 4.09 4.74 5.79 (2.34) 6.28 6.39 5.52 3.80 +3.5 pt
ROIC 4.32 4.29 1.47 6.47 6.61 6.80 (0.51) 7.83 7.65 6.82 9.59 +2.5 pt
ROE 8.86 33.94 (3.15) 12.55 13.02 13.99 (5.44) 13.50 12.30 10.22 8.23 +1.4 pt
People
People Employees 530 530 520 520 505 535 560 570 600 890 — +5.9%
Revenue/emp, $m 1.66 1.96 1.88 1.85 1.87 2.03 2.01 1.97 1.90 1.22 — (3.4%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Prestige Consumer Healthcare Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AMLX Amylyx Pharmaceuticals, Inc. $3.5B — (loss-making) — (loss-making) −100.61% (below 0%: shrinking) n/m −24.50% (below 0%: shrinking) 100.00% 0.00% Compare
RGC Regencell Bioscience Holdings Limited $2.6B — (loss-making) — — — +57.15% (above 0%: growing) 0.00% — Compare
HCM HUTCHMED (China) Limited Sponsored ADR $2.5B — (loss-making) — +510.07% (above 0%: growing) +419.25% (above 0%: growing) +113.21% (above 0%: growing) 60.90% 0.00% Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78% Compare
PRGO Perrigo Company plc $2.2B — (loss-making) — (loss-making) −5.24% (below 0%: shrinking) n/m +138.48% (above 0%: growing) 32.45% 2.34% Compare
PBH Prestige Consumer Healthcare Inc. $2.1B 13.7× 11.7× +22.69% (above 0%: growing) −38.37% (below 0%: shrinking) −38.18% (below 0%: shrinking) 51.30% 24.00%
TRLV Trulieve Cannabis Corp. $2.1B — (loss-making) — (loss-making) −20.12% (below 0%: shrinking) n/m +24.49% (above 0%: growing) 64.30% 0.00% Compare
BCRX BioCryst Pharmaceuticals, Inc. $2.0B — (loss-making) — (loss-making) +13.11% (above 0%: growing) +150.00% (above 0%: growing) −18.69% (below 0%: shrinking) 99.13% 29.58% Compare
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
Median of peers $2.3B — — +13.11% +284.63% +40.82% 62.60% 2.34%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 29 June 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 6.00m 825.50k 134.39
2025 6.19m 7.58m 194.96
2024 5.76m 9.71m 164.57
2023 5.58m 9.54m 142.06
2022 6.03m 9.91m 120.10

Ownership

Directors and executive officers, together 1.50%
BlackRock, Inc. 15.90%
Ariel Investments, LLC 8.70%
Dimensional Fund Advisors LP 6.10%
Vanguard Portfolio Management 6.00%
Vanguard Capital Management 5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Prestige Consumer Healthcare Inc. (PBH) Latest News

6 Nov

Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · Simply Wall St.
Impact 3 · · GlobeNewswire

15 Oct

Impact 4 · · Zacks

29 Sep

Impact 3 · · Simply Wall St.

28 Sep

Impact 4 · · Simply Wall St.

27 Sep

Impact 4 · · MarketBeat

13 Aug

Impact 4 ·
Impact 3 · · The Motley Fool transcript

8 Aug

Impact 4 ·
Impact 3 · · MarketBeat transcript

7 Aug

Impact 4 ·

6 Aug

Impact 3 · transcript
Impact 3 · · Moby
Impact 3 ·
Impact 3 ·
Impact 3 ·

4 Aug

Impact 3 ·

6 Jul

Impact 4 ·

4 Jul

Impact 4 ·

15 Jun

Impact 4 ·

14 Jun

Impact 4 ·

15 May

Impact 4 · · MarketBeat
Impact 3 · · Simply Wall St.

14 May

Impact 4 · · MT Newswires
Impact 3 · · GuruFocus.com
Impact 3 · · MT Newswires
Impact 3 · · Zacks
Impact 3 · · Moby transcript

PBH metrics, ten years each

stockrow.com/PBH · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com